Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Oct 1 - Oct 6
Yellow Card scheme MHRA
Last reviewed: July 14, 2026 Last updated: July 14, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP
A landmark, randomized, double-blind renal health study: reduces the risk of major kidney disease events by 24%, 50% greater decline in eGFR or death from renal/CV causes reduces cardiovascular (CV) events by 18%, and 20% reduction in all-cause mortality in patients with type 2 diabetes and chronic kidney disease
US$ 23.45
US$ 29.84
US$ 27.54
US$ 27.02
